Literature DB >> 19283415

Ashkenazi Parkinson's disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries.

Anat Bar-Shira1, Carolyn M Hutter, Nir Giladi, Cyrus P Zabetian, Avi Orr-Urtreger.   

Abstract

The LRRK2 G2019S mutation is a major genetic determinant of Parkinson's disease (PD) across the world that occurs at an elevated frequency in Ashkenazi Jews. We determined the LRRK2 haplotypes in 77 G2019S carriers, mostly Ashkenazi Jews, and in 50 noncarrier Ashkenazi PD patients, using 16 genetic markers. A single haplotype was detected in all mutation carriers, indicating that these individuals share a common founder. Using a maximum-likelihood method, we estimate that Ashkenazi Jews with G2019S share a common ancestor who lived approximately 1,830 (95% CI 1,560-2,160) years ago, around the second century, after the second Jewish Diaspora.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19283415     DOI: 10.1007/s10048-009-0186-0

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  28 in total

1.  Estimating the age of rare disease mutations: the example of Triple-A syndrome.

Authors:  E Genin; A Tullio-Pelet; F Begeot; S Lyonnet; L Abel
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

2.  LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Laurie J Ozelius; Geetha Senthil; Rachel Saunders-Pullman; Erin Ohmann; Amanda Deligtisch; Michele Tagliati; Ann L Hunt; Christine Klein; Brian Henick; Susan M Hailpern; Richard B Lipton; Jeannie Soto-Valencia; Neil Risch; Susan B Bressman
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

3.  Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease.

Authors:  C P Zabetian; H Morino; H Ujike; M Yamamoto; M Oda; H Maruyama; Y Izumi; R Kaji; A Griffith; B C Leis; J W Roberts; D Yearout; A Samii; H Kawakami
Journal:  Neurology       Date:  2006-05-25       Impact factor: 9.910

4.  The ancestry of LRRK2 Gly2019Ser parkinsonism.

Authors:  Hani T S Benamer
Journal:  Lancet Neurol       Date:  2008-09       Impact factor: 44.182

5.  LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago.

Authors:  Cyrus P Zabetian; Carolyn M Hutter; Dora Yearout; Alexis N Lopez; Stewart A Factor; Alida Griffith; Berta C Leis; Thomas D Bird; John G Nutt; Donald S Higgins; John W Roberts; Denise M Kay; Karen L Edwards; Ali Samii; Haydeh Payami
Journal:  Am J Hum Genet       Date:  2006-08-17       Impact factor: 11.025

6.  A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease.

Authors:  L Warren; R Gibson; L Ishihara; R Elango; Z Xue; A Akkari; L Ragone; Rajesh Pahwa; Joseph Jankovic; Martha Nance; Alan Freeman; Ray L Watts; F Hentati
Journal:  Parkinsonism Relat Disord       Date:  2007-04-11       Impact factor: 4.891

7.  Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism.

Authors:  Owen A Ross; Cleanthe Spanaki; Alida Griffith; Chin-Hsien Lin; Jennifer Kachergus; Kristoffer Haugarvoll; Helen Latsoudis; Andreas Plaitakis; Joaquim J Ferreira; Cristina Sampaio; Vincenzo Bonifati; Ruey-Meei Wu; Cyrus P Zabetian; Matthew J Farrer
Journal:  Parkinsonism Relat Disord       Date:  2008-10-26       Impact factor: 4.891

8.  The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.

Authors:  J P Struewing; D Abeliovich; T Peretz; N Avishai; M M Kaback; F S Collins; L C Brody
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

9.  Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease.

Authors:  K Haugarvoll; R Rademakers; J M Kachergus; K Nuytemans; O A Ross; J M Gibson; E-K Tan; C Gaig; E Tolosa; S Goldwurm; M Guidi; G Riboldazzi; L Brown; U Walter; R Benecke; D Berg; T Gasser; J Theuns; P Pals; P Cras; P Paul De Deyn; S Engelborghs; B Pickut; R J Uitti; T Foroud; W C Nichols; J Hagenah; C Klein; A Samii; C P Zabetian; V Bonifati; C Van Broeckhoven; M J Farrer; Z K Wszolek
Journal:  Neurology       Date:  2008-03-12       Impact factor: 9.910

10.  The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor.

Authors:  S Goldwurm; A Di Fonzo; E J Simons; C F Rohé; M Zini; M Canesi; S Tesei; A Zecchinelli; A Antonini; C Mariani; N Meucci; G Sacilotto; F Sironi; G Salani; J Ferreira; H F Chien; E Fabrizio; N Vanacore; A Dalla Libera; F Stocchi; C Diroma; P Lamberti; C Sampaio; G Meco; E Barbosa; A M Bertoli-Avella; G J Breedveld; B A Oostra; G Pezzoli; V Bonifati
Journal:  J Med Genet       Date:  2005-11       Impact factor: 6.318

View more
  9 in total

1.  Homozygosity for the MTX1 c.184T>A (p.S63T) alteration modifies the age of onset in GBA-associated Parkinson's disease.

Authors:  Ziv Gan-Or; Anat Bar-Shira; Tanya Gurevich; Nir Giladi; Avi Orr-Urtreger
Journal:  Neurogenetics       Date:  2011-08-12       Impact factor: 2.660

2.  Clinical expression of LRRK2 G2019S mutations in the elderly.

Authors:  Marta San Luciano; Richard B Lipton; Cuiling Wang; Mindy Katz; Molly E Zimmerman; Amy E Sanders; Laurie J Ozelius; Susan B Bressman; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

Review 3.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

4.  The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins.

Authors:  Mark S Moehle; João Paulo Lima Daher; Travis D Hull; Ravindra Boddu; Hisham A Abdelmotilib; James Mobley; George T Kannarkat; Malú G Tansey; Andrew B West
Journal:  Hum Mol Genet       Date:  2015-04-29       Impact factor: 6.150

5.  LRRK2 G2019S mutation: frequency and haplotype data in South African Parkinson's disease patients.

Authors:  Soraya Bardien; Angelica Marsberg; Rowena Keyser; Debbie Lombard; Suzanne Lesage; Alexis Brice; Jonathan Carr
Journal:  J Neural Transm (Vienna)       Date:  2010-06-11       Impact factor: 3.575

6.  Identification of population substructure among Jews using STR markers and dependence on reference populations included.

Authors:  Jennifer B Listman; Deborah Hasin; Henry R Kranzler; Robert T Malison; Apiwat Mutirangura; Atapol Sughondhabirom; Efrat Aharonovich; Baruch Spivak; Joel Gelernter
Journal:  BMC Genet       Date:  2010-06-14       Impact factor: 2.797

7.  Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.

Authors:  Min Liu; Samantha A Bender; Gregory D Cuny; Woody Sherman; Marcie Glicksman; Soumya S Ray
Journal:  Biochemistry       Date:  2013-03-01       Impact factor: 3.162

8.  Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population.

Authors:  Xinmin Liu; Rong Cheng; Miguel Verbitsky; Sergey Kisselev; Andrew Browne; Helen Mejia-Sanatana; Elan D Louis; Lucien J Cote; Howard Andrews; Cheryl Waters; Blair Ford; Steven Frucht; Stanley Fahn; Karen Marder; Lorraine N Clark; Joseph H Lee
Journal:  BMC Med Genet       Date:  2011-08-03       Impact factor: 2.103

9.  Evidence for prehistoric origins of the G2019S mutation in the North African Berber population.

Authors:  Rafiqua Ben El Haj; Ayyoub Salmi; Wafa Regragui; Ahmed Moussa; Naima Bouslam; Houyam Tibar; Ali Benomar; Mohamed Yahyaoui; Ahmed Bouhouche
Journal:  PLoS One       Date:  2017-07-19       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.